IL22 and metabolic dysfunction-associated steatohepatitis: developed a fusion protein of IL‐22 that successfully targeted the liver in different in vivo models of metabolic dysfunction‐associated non‐alcoholic steatohepatitis and significantly reduced chronic liver inflammation [92].